Shares of Anavex Life Sciences Corp (NASDAQ:AVXL) have earned an average rating of “Buy” from the seven brokerages that are currently covering the firm, MarketBeat.com reports. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The average twelve-month price target among analysts that have issued ratings on the stock in the last year is $10.75.
Several analysts recently issued reports on AVXL shares. Dawson James started coverage on shares of Anavex Life Sciences in a research report on Wednesday, July 24th. They issued a “buy” rating and a $16.00 price target for the company. ValuEngine downgraded shares of Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Wednesday, October 2nd. Finally, Zacks Investment Research downgraded shares of Anavex Life Sciences from a “buy” rating to a “hold” rating in a research report on Thursday.
A number of hedge funds and other institutional investors have recently bought and sold shares of AVXL. JPMorgan Chase & Co. acquired a new stake in Anavex Life Sciences in the 2nd quarter valued at $38,000. FormulaFolio Investments LLC bought a new position in Anavex Life Sciences during the 3rd quarter valued at $44,000. Kessler Investment Group LLC lifted its stake in Anavex Life Sciences by 418.0% during the 3rd quarter. Kessler Investment Group LLC now owns 20,721 shares of the biotechnology company’s stock valued at $65,000 after acquiring an additional 16,721 shares in the last quarter. Foster Victor Wealth Advisors LLC bought a new position in Anavex Life Sciences during the 3rd quarter valued at $76,000. Finally, D. E. Shaw & Co. Inc. bought a new position in Anavex Life Sciences during the 2nd quarter valued at $120,000. 22.46% of the stock is owned by institutional investors and hedge funds.
Anavex Life Sciences (NASDAQ:AVXL) last announced its quarterly earnings data on Wednesday, August 7th. The biotechnology company reported ($0.14) EPS for the quarter, topping the consensus estimate of ($0.17) by $0.03. On average, analysts anticipate that Anavex Life Sciences will post -0.63 earnings per share for the current fiscal year.
Anavex Life Sciences Company Profile
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company's lead drug candidate is ANAVEX 2-73, which has completed Phase 2a clinical trial for Alzheimer's disease; and preclinical clinical trials to treat Parkinson's disease, Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis.
Recommended Story: What are no-load funds?
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.